

Location: Webconference

Attendees:

○ **Panel Members:**

Torsten Bohn, Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico Hirsch-Ernst, Helle Katrine Knutsen, Alexandre Maciuk, Inge Mangelsdorf, Harry J. McArdle, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, Sophia Tsaouri, Dominique Turck (Chair) and Marco Vinceti.

○ **Hearing Experts¹:**

Marta Crous Bou participated for agenda item 7, via web conference.

○ **European Commission:**

Ivona Babic, Stephanie Bodenbach

○ **EFSA:**

Nutrition & Food Innovation (NIF) Unit: Agnès de Sesmaisons, Lucia Fabiani, Thibault Fiolet, Wolfgang Gelbmann, Andrea Germini, Leng Heng, Nena Karavasiloglou, Eirini Kouloura, Leonard Matijer, Estefanía Noriega Fernández, Ruth Roldán Torres, Angeliki Sofroniou, Ariane Titz, Silvia Valtueña, and Ermolaos Ververis.

○ **Others:**

Katerina Gerazova participated as ISA (Individual Scientific Advisor) contractor (ref. EOI/EFSA/NUTRI/2019/1) for agenda item 5.

1. Welcome and apologies for absence

The Chair welcomed the participants.

2. Adoption of agenda

The agenda was adopted without changes.

3. Declarations of Interest of Panel members

In accordance with EFSA's Policy on Independence² and the Decision of the Executive Director on Competing Interest Management³, EFSA screened the Annual Declarations of Interest filled out by the Working Group members invited to the present meeting. No Conflicts of Interest related to the issues discussed in this meeting have been identified during the screening process.

Certain interests were declared orally by the members before the beginning of the meeting. For further details on the outcome of the screening of the Oral Declaration of Interest made at the beginning of the meeting, please refer to the Annex.

¹ As defined in Article 17 of the Decision of the Executive Director concerning the selection of members of the Scientific Committee, the Scientific Panels, and the selection of external experts to assist EFSA with its scientific work: <http://www.efsa.europa.eu/en/keydocs/docs/expertselection.pdf>

² http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf

³ http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf



4. Agreement of the minutes of the 131st Plenary meeting held on 14 December 2022 via web-conference

[The minutes](#) of the 131st Plenary meeting were agreed by written procedure on 19 December 2022.

5. Draft opinion on Xia Powder 435 (NF 2021-1311) - Applicant: Functional Products Trading Arica S.A./BENEXIA (EFSA-Q-2021-00551)

The draft opinion was presented on 27 February. The Panel reviewed and discussed the sections related to product characterization, specifications, history of use, proposed uses and use levels, nutritional information, toxicological information and allergenicity of the novel food. The opinion was adopted by the Panel on 27 February, subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal [here](#).

6. Draft scientific opinion on the Tolerable Upper Intake Level for Vitamin B6 (EFSA-Q-2021-00369)

The comments received from the public consultation of the draft scientific opinion on the revision of the UL for vitamin B6 were presented and discussed on 27 February. Feedback received from the Panel will be considered by the Working Group on Upper Levels (WG ULs). The draft opinion will be presented to the NDA Panel for discussion/possible adoption at its plenary meeting on 28-30 March 2023.

7. Draft scientific opinion on the revision of the Tolerable Upper Intake Level for folic acid/folate (EFSA-Q-2021-00366)

The available body of evidence regarding the relationship between folate/folic acid intake and risk of colorectal cancer was presented and discussed on 27 February. Feedback received from the Panel will be considered by the WG ULs. The draft opinion will be presented to the NDA Panel for discussion/possible endorsement for release for public consultation at its plenary meeting on 28-30 March 2023.

8. Draft opinion on water lentil protein concentrate from a mixture of Lemna gibba and Lemna minor (NF 2018/0801) – Applicant: ABC Kroos B.V. (EFSA-Q-2019-00047)

The draft opinion was presented on 28 February. The Panel reviewed and discussed the sections related to product characterization, production process, specifications, history of use, proposed uses and use levels, ADME, nutritional information, toxicological information and allergenicity of the novel food. The opinion was adopted by the Panel on 28 February, subject to the incorporation of editorial changes. The full text of the opinion will be available in the coming weeks in the EFSA Journal [here](#).



9. EFSA's Scientific Colloquium 27: Cell culture-derived foods and food ingredients

The Panel was informed about the 27th EFSA Scientific Colloquium on "Cell culture-derived foods and food ingredients" ([link](#)), which will take place in Brussels on 11-12 May 2023 (the plenary sessions will also be web-streamed). The Scientific Colloquium will focus on the fields of cell culture-derived foods of animal or plant origin* and precision fermentation**. EFSA will bring together relevant experts and stakeholders to discuss research and innovation developments in those fields and the impact of emerging safety and methodological aspects on EFSA's risk assessment approaches.

*In absence of a legal definition, and just for the purpose of the colloquium, cell culture-derived foods of animal or plant origin refer to foods produced by the propagation of animal or plant cells, respectively, assisted by tissue engineering techniques.

**In absence of a legal definition, and just for the purpose of the colloquium, precision fermentation refers to the use of engineered microorganisms in the production of food ingredients.

10. Feedback from the Scientific Committee /Scientific Panels, EFSA, the European Commission

Postponed.

11. Any Other Business

- The Panel was informed about the ongoing work for the protocol development to address the mandates related to Article 8(2) of Regulation (EC) No 1925/2006. The Panel was consulted on some specific questions raised by the WG on substances other than vitamins and minerals. Feedback received from the Panel will be discussed by the [WG on substances other than vitamins and minerals](#).
- The Panel was informed about the two on-line NDA Thematic Workshops. The intention of these workshops is to collect the views of the participants and possible orientations (in a Workshop report) that will be considered by the NDA Panel in revising its guidance.

The first workshop on "Setting principles for human-to-human scaling approaches for the derivation of tolerable upper intake levels (UL)" (28 Feb-1 March 2023) is organised in the context of the Panel on-going review of the ULs for selected vitamins and minerals. It aims to define criteria for the selection of the appropriate scaling method to adjust UL for a particular population group (e.g. adults) to other groups (e.g. infants, children).

The second workshop on "derivation of conversion factors for new sources & forms of nutrients" (9 March 2023) aims to share and exchange views regarding the scientific principles and data requirements for deriving conversion factors for proposed new sources or forms of nutrients. The context relates to the Commission request to EFSA to update its [Guidance on safety evaluation of sources of nutrients and bioavailability of nutrient from the sources](#) regarding the scientific principles and data requirements for applicants in order to derive a conversion factor for proposed new sources or forms of nutrients. Preceding the workshop, EFSA held an open consultation through an Expert Survey on key points to consider for derivation of conversion factors (15/12/2022-20/01/2023).

- The next Plenary meeting of the NDA Panel will be held on 28–30 March 2023 via web-conference. The open session to observers will be held on 29-30 March.



Annex

Interests and actions resulting from the Oral Declaration of Interest done at the beginning of the meeting

NO CONFLICT: With regard to this meeting, Dr Marco Vinceti declared the following interest: receipt of two new research funds on "Epidemiologic investigation on the effects of selenium exposure through drinking water in the Reggio Emilia area on the risk of diabetes" (funded by: Fondazione Cassa di Risparmio di Reggio Emilia Pietro Manodori) and "Biocidal Nanocompounds implementation and production" (funded by: INAIL (Rome) - Istituto nazionale per l'assicurazione contro gli infortuni sul lavoro). In accordance with EFSA's Policy on Independence⁴ and the Decision of the Executive Director on Competing Interest Management⁵, and taking into account the specific matters discussed at the meeting in question, the interest above was not deemed to represent a Conflict of Interest for the expert concerned.

⁴ http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/policy_independence.pdf

⁵ http://www.efsa.europa.eu/sites/default/files/corporate_publications/files/competing_interest_management_17.pdf